Related Experiment Videos
The effects of ML 3000 on antigen-induced responses in sheep
W M Abraham1, S Laufer, S Tries
1Division of Pulmonary and Critical Care Medicine, University of Miami at Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, Florida, 33140, USA.
Abstract:
ML 3000 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO), two enzymes that contribute to the airway inflammation in asthma. When administered as an aerosol at a dose of 100 mg, 0.5 h before antigen challenge in allergic sheep, ML 3000 provided significant inhibition against the early bronchial response (EAR, mean 33% protection, P<0.05), completely blocked the late antigen-induced bronchoconstriction (LAR, mean 81% protection, P<0. 05) and the airway hyperresponsiveness (AHR, P<0.05) to aerosolized carbachol that occurs 24 h after antigen challenge in this model. Consistent with this functional protection was a small but significant reduction in the percentage of neutrophils recovered in bronchoalveolar lavage (BAL) at 8 h and 24 h after challenge. These findings are similar to previous data obtained in this animal model with other 5-LO inhibitors (blockade of the LAR and AHR) and COX inhibitors (blockade of AHR). These results suggest that aerosol administration of a dual inhibitor of COX and 5-LO may have beneficial effects in the treatment of allergic airway disease.
Insights
ML 3000, a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO), effectively reduced airway inflammation and bronchoconstriction in allergic sheep. This asthma treatment candidate demonstrated significant protection against early and late airway responses.
Area of Science:
- Pharmacology
- Immunology
- Respiratory Medicine
Background:
- Asthma involves airway inflammation driven by enzymes like cyclooxygenase (COX) and 5-lipoxygenase (5-LO).
- Dual inhibitors targeting both COX and 5-LO pathways offer a potential therapeutic strategy for allergic airway diseases.
Purpose of the Study:
- To evaluate the efficacy of ML 3000, a dual COX and 5-LO inhibitor, in an allergic sheep model of asthma.
- To assess the impact of aerosolized ML 3000 on early and late asthmatic responses, airway hyperresponsiveness, and inflammatory cell infiltration.
Main Methods:
- Allergic sheep were challenged with antigen after aerosolized administration of ML 3000 (100 mg).
- Early Bronchial Response (EAR), Late Antigen-induced Bronchoconstriction (LAR), and airway hyperresponsiveness (AHR) to carbachol were measured.
- Neutrophil counts in bronchoalveolar lavage (BAL) fluid were assessed at 8 and 24 hours post-challenge.
Main Results:
- ML 3000 significantly inhibited the EAR (33% protection) and completely blocked the LAR (81% protection).
- A significant reduction in AHR to carbachol was observed 24 hours after antigen challenge.
- A small but significant decrease in neutrophil percentage in BAL fluid was noted at 8 and 24 hours.
Conclusions:
- Aerosolized ML 3000 demonstrates potent anti-inflammatory and bronchodilatory effects in a relevant asthma model.
- Dual inhibition of COX and 5-LO pathways via ML 3000 shows promise for treating allergic airway diseases.
- The findings support further investigation of ML 3000 as a therapeutic agent for asthma management.